Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
The $1.4M quarter keeps the lights on. The reaffirmed $30-35M 2026 revenue and 28% EBITDA margin target signals pipeline visibility intact. The next catalyst is a quarterly revenue step-up that shows the ramp is underway.
Net operating income rose 28.6% to $12.1 million, outpacing revenue growth and lifting the margin to 84%. The print sets up a test of lease renewal pricing power.
M-tron Industries' Q1 2026 earnings call transcript is out, but the prepared remarks stop at legal disclaimers. The actual numbers and guidance remain the next catalyst.
CEO Sean Browne and CFO Scott Neils led the May 13 call, directing investors to non-GAAP reconciliations and an 8-K narrative. The heavy risk language before any numbers signals a wide range of possible outcomes.
Evolution Petroleum (EPM) expects 23 wells online and 100 net BOE/d lift at TexMex in fiscal Q4, following one-time Q3 hedge losses. Dividend confidence remains.
Six sell-side banks dialed into Lundbeck's Q1 2026 call before any numbers were released. The CEO's 'proof point' language sets a high bar for the financials that follow.
Dr Reddy's net profit tumbled 86% YoY, pointing to a likely one-time charge. Goldman Sachs and Morgan Stanley are now assessing whether the core generics business remains on track.
Velo3D posted a 48% revenue jump in Q1 2026, reiterated $60M-$70M full-year guidance, and targeted gross margins above 30% in the second half. The next catalyst is the Q2 margin trend.
CEO Arun Jeldi cited accelerating momentum and expanding demand on the Q1 2026 call. The warrant (VLDXW) reaction hinges on whether the $60M-$70M full-year guide holds.
Parks! America plans up to $0.5M in digital signage after March demand softened. The next test is whether per-visitor spending rises as marketing fixes kick in.
Oklo’s Q1 call transcript omits revenue and earnings. The participant list—Goldman, Cantor, B. Riley among others—maps the institutional desks pricing the name as an option on NRC approval.
Management expects Q3 and Q4 each above $10M. The J&J catheter transition adds execution risk, and Q2 shipment data will test the ramp.
First-quarter revenue hit $19.8 million and adjusted EBITDA reached $3.3 million, each above the Street view. The release provided no full-year outlook or segment split, making the Q&A session the next real catalyst.
The raised 2026 guide and 4-7 year written contingent demand commitments change the pitch for Karman: a backlog conversion story with a $1B+ cushion.
CEO Thomas Berge framed the European CPaaS leader with 66,000 customers and roughly 700 employees. The Q1 print must now show that post-merger scale translates into EBITDA growth.
The Q1 2026 earnings call presentation for Voyager Technologies is now public. Investors will scrutinize the deck for backlog growth, cash consumption rates, and any revision to the full-year outlook. The stock's next leg depends on the details inside.
Global Dominion Access, S.A. posted its Q1 2026 earnings call presentation on May 12, giving OTC-traded GBDMF holders their first detailed look at the quarter. The deck typically covers revenue, margins, and guidance.
Niterra Co., Ltd. posted its Q4 2026 earnings presentation on May 12, giving US ADR holders under NGKSY access to full-year financials and guidance. The deck is the main catalyst before Tokyo trading.
Q1 sales rose 19% after TYR and Alien Gear deals closed. Full-year guidance stayed at $736M-$758M. Margin delivery from those acquisitions is the next test.
Revenue surged 121.7% to C$55.2M; a C$4.4M net loss leaves the path to positive cash flow undefined. The next catalyst is management commentary on margin progression.
Q2 adjusted EPS of $0.48 annualizes below the $2.00 low end. With full-year guidance intact, the second half must deliver roughly $1.04-$1.24 in EPS, leaving little room for revenue deceleration.
The Q1 2026 call opened without financials in the transcript. Pre-call April data and retail-upvoted questions intensify the event, leaving markets exposed to the imminent guidance.
Arvinas' Q1 call transcript lacked financials. Analysts from Goldman Sachs and Evercore attended, signaling institutional focus on the upcoming 10-Q filing.
Camtek's Q1 transcript offers no headline beat. Order backlog, HBM demand, and margin quality will determine if CAMT is a structural growth play or a cycle trade.
Ralliant raised 2026 adjusted EPS to $2.53-$2.69, targeting $50M-$60M savings by 2028. A $1B defense backlog and Test & Measurement growth back the outlook.
Ralliant’s Q1 2026 earnings call transcript is live. With prior guidance of $2.53–$2.69 EPS and $50M–$60M savings, here’s the read on whether the quarter kept that path intact.
Allstate's Alpha Score sits at 67/100, reflecting a market in wait-and-see mode. The next combined ratio print will test whether the underwriting turnaround can narrow the valuation gap with Chubb.
Record backlog and raised guidance support 14% EPS growth. Middle East exposure and AI contract lumpiness pose execution risks. Next catalyst: backlog conversion.
A hotter-than-expected March CPI print knocked index futures lower Tuesday, raising the stakes for company-specific catalysts from Bristol-Myers, Novo Nordisk, Broadcom, and Alphabet. The inflation surprise pushes the next Fed decision into sharper focus.
Pangaea Logistics Solutions released its Q1 2026 earnings call presentation, offering a detailed look at fleet performance and dry bulk market conditions. The deck sets up the conference call for forward-looking commentary.